EcoDrugPlus

Calcium Channel, Voltage-Dependent, Gamma Subunit 2a

Ensembl ID : ENSGACG00000014558
Gene Symbol: CACNG2A
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSGACG00000012203
Gene Symbol: CACNG4B
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5a

Ensembl ID : ENSGACG00000018521
Gene Symbol: CACNG5A
1 Cross references
184 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSGACG00000002008
Gene Symbol: CACNG6A
1 Cross references
181 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSGACG00000002018
Gene Symbol: CACNG7A
1 Cross references
188 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSGACG00000002014
Gene Symbol: CACNG8A
1 Cross references
168 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSGACG00000020687
Gene Symbol: CASR
1 Cross references
203 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSGACG00000012647
Gene Symbol: CACNA2D1
1 Cross references
229 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSGACG00000001540
Gene Symbol: CACNA2D2
1 Cross references
200 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSGACG00000010123
Gene Symbol: CACNA2D3
2 Cross references
216 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSGACG00000019690
Gene Symbol: CACNA2D4
1 Cross references
234 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSGACG00000008453
Gene Symbol: CACNA2D4
1 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).